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In search of alternatives to antimicrobial agents currently in use, 
and in order to respond to the landscape of loss of efficacy due to the 
emergence of resistance, several research groups are evaluating several 
familiesof compounds, among them the quinoxaline derivatives family, 
which presented several other potential biological applications.
Quinoxaline derivatives are an important class of heterocyclic 
compounds, where N replaces some carbon atoms in the ring. 
Quinoxaline molecular formula is C8H6N2 and is formed by two 
aromatic rings, benzene and pyrazine. It is rare in natural state, but 
their synthesis is easy to perform [1]. Modifying its structure is possible 
to obtain a wide variety of compounds with different biological 
properties.
In the last two decades, several quinoxaline derivatives have been 
tested and presented antimicrobial activity, as antifungal [2-4] and 
antibacterial agents [2-13]. The antibacterial activity observed covers 
both Gram-negative and Gram-positive bacteria [6,8,11-13], including 
Mycobacterium species [4,7,9,10,14,15]. There are also data pointing 
to activity against multidrug resistant Mycobacterium tuberculosis 
[15]. Several studies have been described, concerning synthesis and 
biological activity of a large amount of quinoxalines. Some quinoxaline 
1,4-di-N-oxide derivatives have been shown to inhibit M. tuberculosis 
to a rate of 99 to 100% [9,16].
Antifungal activity for quinoxaline derivatives has been tested 
against Candida albicans [17,18]. Thieno[2,3-d]-pyrimidines and 
pyrrolo[3,4-b]-quinoxalines  were among the synthesized compounds 
that presented this kind of biological activity. Researchers also reported 
some 2-sulphonyl quinoxalines and 3-[(alkylthio) methyl] quinoxaline-
1-oxide derivatives as compounds with high antifungal activity [4], and 
also pyrazolo quinoxalines which were observed to be active against
fungal infections [19].
There are quinoxaline derivatives that present anti-protozoan 
activity [20,21], especially anti-amoebic [22-24], against Plasmodium 
and Leishmania species (strain MHOM/BR/76/LTB-012A) [21,25]. 
Compounds with one halogenous group in position 6 and 7 of the 
quinoxaline core provide an efficient approach for further development 
of antimalarial and antileishmanial agent [21].
Quinoxaline derivatives present other biological properties.  Anti-
cancer activity has been already studied [26-28], and results obtained 
are very promising. Recently, our research group has demonstrated 
anti-proliferative activity in several cancer cell lines. 
Antioxidant and anti-inflammatory activity has also been explored 
for quinoxaline derivatives [29-31]. Some compounds presented anti-
inflammatory effect similar to the reference drug used, indomethacin 
[29]. 
Some cooper and zinc quinoxaline derivative complexes have 
presented antidiabetic activity [32] and N-arylcarbamoyl and N-aryl 
thiocarbamoyl derivatives revealed hypoglycemic behavior in Wister 
rats. 
Quinoxaline-5,8-diones derivatives were tested for their inhibitory 
activity on rat aortic smooth muscle cell proliferation and results 
revealed good proliferation inhibition.Thus the quinoxaline-5,8-diones 
were found as promising anti-atherosclerotic agents [16,19,33].
New series of structurally novel 3-substituted-2-carboxamides 
quinoxaline exhibited 5-HT3 (serotonin) receptor antagonism, and 
some of them showed antagonism greater than the standard TCA 
(Tricyclic anti-depressant) drugs [34].
A series of 7-heterocycle-substituted quinoxaline carboxylic acids 
were tested for their neuroprotective efficacy. One of the synthesized 
compounds was found to possess high neuroprotective effect in vitro 
and showed excellent in vivo activity [35].
Due to the wide range of applications, quinoxaline derivative 
compounds have aroused the interest of the scientific community, 
especially in the last decade. Given the ability to design different 
structures from the quinoxaline core, improvement of biological 
activities may be achieved, as well as new applications.
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